Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

Blood Cancer J. 2017 Feb 3;7(2):e520. doi: 10.1038/bcj.2017.1.

Authors

R T Swords¹, J Watts¹, H P Erba², J K Altman³, M Maris⁴, F Anwer⁵, Z Hua⁶, H Stein⁶, H Faessel⁶, F Sedarati⁶, B J Dezube⁶, F J Giles³, B C Medeiros⁷, D J DeAngelo⁸

Affiliations

¹ Leukemia Program, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
² Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
³ Northwestern Medicine Developmental Therapeutics Institute, Northwestern University, Chicago, IL, USA.
⁴ Colorado Blood Cancer Institute, Denver, CO, USA.
⁵ University of Arizona Cancer Center, Tucson, AZ, USA.
⁶ T Takeda Pharmaceuticals International Co., Cambridge, MA, USA.
⁷ Division of Hematology, Stanford University School of Medicine, Stanford, CA, USA.
⁸ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

No abstract available

Publication types

Clinical Trial, Phase I
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Cyclopentanes / administration & dosage
Cyclopentanes / adverse effects*
Enzyme Inhibitors / administration & dosage
Enzyme Inhibitors / adverse effects*
Female
Humans
Leukemia, Myeloid, Acute / drug therapy*
Male
Maximum Tolerated Dose
Middle Aged
Myelodysplastic Syndromes / drug therapy*
NEDD8 Protein / antagonists & inhibitors
Pyrimidines / administration & dosage
Pyrimidines / adverse effects*
Young Adult

Substances

Cyclopentanes
Enzyme Inhibitors
NEDD8 Protein
NEDD8 protein, human
Pyrimidines
pevonedistat

Associated data

ClinicalTrials.gov/NCT00677170

Grants and funding

KL2 TR000461/TR/NCATS NIH HHS/United States